Investors and Media

Investors and Media

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Corporate Profile

Corporate Presentation (April 2026)

Corporate Presentation (April 2026)

ASX Announcements

Quarterly Cashflow Report - Period ending 31 March 2026

Quarterly Cashflow Report - Period ending 31 March 2026

FDA Confirms Single Pivotal Trial Pathway for Elate Ocular

FDA Confirms Single Pivotal Trial Pathway for Elate Ocular

Quarterly Cashflow Report - Period ending 31 December 2025

Quarterly Cashflow Report - Period ending 31 December 2025

Cambium Bio Secures A$2.4 Million Strategic Investment from Major Shareholder ZYBT

Cambium Bio Secures A$2.4 Million Strategic Investment from Major Shareholder ZYBT

Quarterly Cashflow Report - Period Ending 30 September 2025

Quarterly Cashflow Report - Period Ending 30 September 2025

For all Cambium Bio Limited ASX market announcements, click here

Financial Information

Half Year Report (December 2025)

Half Year Report (December 2025)

Annual Report (June 2025)

Annual Report (June 2025)

Cambium Bio Limited Half Year Report (December 2024)

Cambium Bio Limited Half Year Report (December 2024)

Cambium Bio Limited Annual Report FY2024

Cambium Bio Limited Annual Report FY2024

Cambium Bio Limited Half Year Report (December 2023)

Cambium Bio Limited Half Year Report (December 2023)

News Releases

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Events and Presentations

Meet Cambium Bio team at BIO International Convention in San Diego (June 2026)

Meet Cambium Bio team at BIO International Convention in San Diego (June 2026)